Table 11.
Comparison of efficacy results from the early treatment studies (18)
| Study | Treatment | Patients: drug/placebo | Multifocal presentationa | Patients with ≥1 Gd+ lesion on initial MRIa | Conversion to CDMS (2 years) | |
|---|---|---|---|---|---|---|
| IFNβ Placebo | ||||||
| CHAMPS | IFNβ-1a IM, qw | 193/190 | 0% | 28% | 20%b | 35%b |
| ETOMS | IFNβ-1a sc, tiw | 154/154 | 39.0% | 58% | 34% | 45% |
| BENEFIT | IFNβ-1b sc, eod | 292/176 | 47.4% | 42% | 28% | 45% |
a
Data for all patients (drug and placebo groups):
b
Patients converting to CDMS at 25 months.
CDMS: clinically definite MS; eod: every other day; Gd+: gadolinium-positive; IFNβ: interferon beta, IM: intramuscular; qw: weekly; sc: subcutaneous; tiw: twice weekly; CHAMPS: Controlled High-Risk Avonex® Multiple Sclerosis Prevention Study; ETOMS: Early Treatment of MS; BENEFIT: Betaferon® in Newly Emerging Multiple Sclerosis for Initial Treatment.